Clinical Trial Update: A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of CF33-hNIS (VAXINIA), an oncolytic virus, given alone or with pembrolizumab, in adults with metastatic or advanced solid tumors; the trial has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bile Duct Cancer
• Cholangiocarcinoma
• Solid Tumors

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• VAXINIA (CF33-hNIS)

Snippet

Sponsor: Imugene Limited | Conditions: Solid Tumor, Solid Carcinoma | Phase 1 | Status: TERMINATED